| ID | 1004 |
| Name of the vaccine | Boostrix |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 10 years and older |
| Description of the vaccine | Tetanus (reduced), Diphtheria (reduced) and Pertussis vaccine (Tdap vaccine) |
| Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
| Name of the manufacturing country | Belgium and Germany |
| Year of manufacture | 2005 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | 0.5 ml injection with initial dose 5 years after the Dtap or Td vaccine. And additional dose 9 years after the Tdap vaccine. |
| Mechanism of action | Serum diphtheria antitoxin level of greater than or equal to 1 IU/ml provides long-term protection. |
| Route of administration | Intramuscular |
| Indications | Not indicated in children aged younger than 10 years. |
| Export | Distributed by - GlaxoSmithKline Research Triangle Park |
| Approval | US FDA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | Also for tetanus and pertussis. |
| Side effects of vaccine | Pain,redness and swelling at the injection site, increase in arm circumference,headache,fatigue and gastrointestinal symptoms. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/124002/download |
| Other name | NA |
| Additional Links | NA
|